Patents Assigned to SUMITOMO PHARMA CO., LTD.
  • N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof
    Patent number: 8541585
    Abstract: The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar1 and Ar2 are aryl or heteroaryl; V is nitrogen, or CR3; W1 is a single bond, —C(O)—, etc.; W2 is C1-alkylene; W3 is a single bond, methylene, —NH—, —CR4?CR5—, etc.; Ring Q is a group of formula (a) in which n is 0 or 1; m is 0 to 2; k is 1 to 3; Z is a single bond, methylene, oxygen, etc.; R1a, R1b and R1c are each, same or different, hydrogen, hydroxyl, halogen, cyano, C1-6 alkyl, etc.; or pharmaceutically acceptable salts thereof are provided.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: September 24, 2013
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Megumi Maruyama, Naoya Kinomura, Satoshi Nojima, Masahiro Takamura, Keisuke Kakiguchi, Hiroto Tatamidani
  • Imidazoquinolines with Immuno-Modulating Properties
    Publication number: 20130225555
    Abstract: The present invention provides compounds of formula (I) wherein Ra, R1, R2, R3, X1, Y1, Z1, A, n and m are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: March 14, 2013
    Publication date: August 29, 2013
    Applicants: Dainippon Sumitomo Pharma Co., Ltd., AstraZeneca AB
    Inventors: AstraZeneca AB, Dainippon Sumitomo Pharma Co., Ltd.
  • CYCLIC AMIDE DERIVATIVE
    Publication number: 20130217692
    Abstract: Provided is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A is C6-10 arylene, etc.; R1a, R1b and R1c each independently is a hydrogen atom, a halogen atom, a C1-4 alkyl group, a C1-4 alkoxy group, etc.; R2 is an optionally substituted C6-10 aryl group, an optionally substituted 5- to 12-membered monocyclic or polycyclic heteroaryl group, an optionally substituted C7-16 aralkyl group, etc.; m is 0, etc.; n is an integer of 0 to 2.
    Type: Application
    Filed: September 2, 2011
    Publication date: August 22, 2013
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Yoshihiro Horiuchi, Hiroaki Fujiwara, Hitoshi Suda, Izumi Sasaki, Mitsutaka Iwata, Kiyoto Sawamura
  • HUMAN MONOCLONAL ANTIBODY
    Publication number: 20130196378
    Abstract: The present invention provides an anti-CD81 antibody usable as a pharmaceutical product for human. Specifically, the present invention provides an anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of the amino acid numbers 80 to 175 in the amino acid sequence shown in SEQ ID NO:22.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 1, 2013
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventor: DAINIPPON SUMITOMO PHARMA CO., LTD.
  • PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES
    Publication number: 20130196388
    Abstract: A process for efficiently producing optically active succinimide derivatives as key intermediates of (3R)-2?-(4-bromo-2-fluorobenzyl)spiro{pyrrolidine-3,4?(1?H)-pyrrolo[1,2-a]pyrazine}-1?,2,3?,5(2?H)-tetraone, which comprises the following reaction steps, and the step 2 is performed by using a non-animal-derived enzyme.
    Type: Application
    Filed: July 28, 2011
    Publication date: August 1, 2013
    Applicants: KYOWA HAKKO BIO CO., LTD., DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Shinji Kita, Kazuya Tsuzaki, Eitora Yamamura
  • Salts 756
    Patent number: 8476288
    Abstract: The invention provides salts of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: July 2, 2013
    Assignees: AstraZeneca AB, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Nicholas James Bennett, Thomas McInally, Austen Pimm, Yoshiaki Isobe
  • Bicyclic heterocyclic compound
    Patent number: 8471038
    Abstract: The invention provides a compound for the treatment or prophylaxis of pathology involving SNS, specifically diseases such as neuropathic pain, nociceptive pain, dysuria, multiple sclerosis and the like.
    Type: Grant
    Filed: December 25, 2009
    Date of Patent: June 25, 2013
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Katsunori Tsuboi, Yusuke Yamai, Hitoshi Watanabe, Hironori Kinoshita
  • TREATMENT DRUG FOR AUTOIMMUNE DISEASES AND ALLERGIC DISEASES
    Publication number: 20130121914
    Abstract: The present invention provides an agent for the prophylaxis or therapy of autoimmune diseases or allergic diseases, which contains an anti-Embigin antibody, particularly an anti-Embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent for the prophylaxis or therapy of diseases involving Th17 cell, and a cytotoxic agent to Th17 cell. In addition, an agent for detection of Th17 cell, which contains an anti-Embigin antibody, a convenient detection method of Th17 cell, which uses the agent, a method of efficiently delivering a drug and the like in a Th17 cell selective manner, which uses an anti-Embigin antibody, and a drug delivery system to Th17 cell are provided.
    Type: Application
    Filed: June 2, 2011
    Publication date: May 16, 2013
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Koichi Kino, Toshihiro Kai, Mitsuhiro Matsumoto, Masunori Kajikawa, Masahito Sugiura, Emi Shimizu
  • Human monoclonal antibody
    Patent number: 8440797
    Abstract: The present invention provides an anti-CD81 antibody usable as a pharmaceutical product for human. Specifically, the present invention provides an anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of the amino acid numbers 80 to 175 in the amino acid sequence shown in SEQ ID NO:22.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: May 14, 2013
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Takamasa Watanabe, Tadahiko Yoshima, Mikael Mattsson, Anna Sarnefalt, Takuya Hasezaki
  • BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20130116227
    Abstract: Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represented by formula (a); L is —CONH—, etc.; R1 is a substitutable aminosulfonyl group, etc.; R2 is a hydrogen atom, etc.; R3 is a hydrogen atom, etc.; R4 is a hydrogen atom, a halogen atom, hydroxy group, a substitutable amino group, a substitutable C1-6 alkoxy group, a substitutable 4- to 7-membered cyclic amino group, etc.; R5a, R5b and R5c are each independently hydrogen atoms, etc.; R6 is a halogen atom, a cyano group, etc.; R7 and R8 are each independently a hydrogen atom, etc.; and m is an integer such as 0.
    Type: Application
    Filed: July 12, 2011
    Publication date: May 9, 2013
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Seiji Katayama, Seiji Hori, Futoshi Hasegawa, Kuniko Suzuki
  • METHOD FOR PREVENTION OR TREATMENT OF METABOLIC SYNDROME
    Publication number: 20130115220
    Abstract: The present invention aims to provide a method for the prophylaxis or treatment of metabolic syndrome, which can discontinue the domino effect-like chain of diseases in metabolic syndrome in the upstream by suppressing infiltration of macrophage into the adipose tissues. The present invention provides a method for the prophylaxis or treatment of a metabolic syndrome, including a step of administering an AIM inhibitor to a subject.
    Type: Application
    Filed: May 20, 2011
    Publication date: May 9, 2013
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventor: Toru Miyazaki
  • Imidazoquinolines with immuno-modulating properties
    Patent number: 8436178
    Abstract: The present invention provides compounds of formula (I) wherein Ra, R1, R2, R3, X1, Y1, Z1, A, n and m are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: May 7, 2013
    Assignees: AstraZeneca AB, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Roger Victor Bonnert, Thomas McInally, Stephen Thom, Hiroki Wada
  • Process for preparing (3R)-2?-(4-bromo-2-fluorobenzyl)spiro-[pyrrolidine-3,4?(1?H)-pyrrolo[1,2-A]pyrazine]-1?,2,3?,5(2H?)-tetraone
    Patent number: 8415487
    Abstract: The present invention is a process for preparing (3R)-2?-(4-bromo-2-fluorobenzyl)spiro-[pyrrolidine-3,4?(1?H)-pyrrolo[1,2-a]pyrazine]-1?,2,3?,5(2H?)-tetraone, comprising, for example, the following steps: (1) reacting a compound of the formula (III) wherein R is a C1-6 alkyl group, with 2,5-dimethoxytetrahydrofuran to provide a compound of the formula (IV) wherein R is a C1-6 alkyl group; (2) reacting the compound of the formula (IV) wherein R is a C1-6 alkyl group, with trichloroacetyl chloride to provide a compound of the formula wherein R is a C1-6 group; and (3) reacting the compound provided in step (2) with 4-bromo-2-fluorobenzylamine to provide (3R)-2?-(4-bromo-2-fluorobenzyl)spiro-[pyrrolidine-3,4?(1?H)-pyrrolo[1,2-a]pyrazine]-1?,2,3?,5(2H?)-tetraone.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: April 9, 2013
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Daisuke Tanaka, Toshiyuki Negoro
  • 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the same, and use of the same
    Patent number: 8389742
    Abstract: The present invention provides 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylates of the formula (I): wherein R1 is a C1-6 alkyl group, etc., R2 is a hydrogen atom or a COOR3 group, wherein R3 is a tert-C4-6 alkyl group, a 2,2,2-trichloroethyl group or a benzyl group in which the benzene ring moiety may be optionally substituted by one or two atoms or groups independently selected from the group consisting of a halogen atom, a C1-4 alkyl group, a C1-4 alkoxy group, a cyano group and a nitro group, and a salt thereof, which are useful as a novel intermediate for preparing tetrahydropyrrolo[1,2-a]pyrazin-4-spiro-3?-pyrrolidine derivatives such as Ranirestat being promising therapeutic agents for diabetic complications in a short process and in an economically advantageous and safe manner, and the process for preparing the same.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: March 5, 2013
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventor: Daisuke Tanaka
  • Bicyclic heterocyclic derivative
    Patent number: 8389511
    Abstract: The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor. [wherein R1a is halogen, etc.; R1m is H, etc.; G1 is —N(R1b)—, etc.; G2 is —CO—, etc.; G3 is —C(R1c)(R1d)—, etc.; G4 is oxygen, etc.; R1b is optionally substituted C1-6 alkyl, etc.; R1c and R1d are independently the same or different, H, etc.; R3 is H, optionally substituted C1-6 alkyl, etc.; R3a, R3b, R3c and R3d are independently the same or different, and a group: -A-B (said A is single bond, etc., and said B is H, etc.), etc.; and n is 1, etc.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: March 5, 2013
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Hiroyuki Nakahira, Yohei Ikuma, Nobuhisa Fukuda, Kozo Yoshida, Hidenori Kimura, Satoshi Suetsugu, Akira Fusano, Kiyoto Sawamura, Junya Ikeda, Yoshio Nakai
  • Orally disintegrating tablet
    Patent number: 8377995
    Abstract: The invention provides an orally disintegrating tablet that has both adequate tablet hardness and rapid disintegrability in the oral cavity, and that undergoes minor hardness reduction and maintains good oral disintegrability even when preserved under moist conditions. In particular, the invention relates to an orally disintegrating tablet containing (a) crystalline cellulose, (b) a calcium hydrogen phosphate compound, (c) a natural starch and (d) a lubricant, wherein the blending ratio to 100 wt % of the disintegrating tablet is (a) 9 to 60 wt %, (b) 16 to 60 wt %, (c) 3 to 40 wt % and (d) 0.01 to 1.8 wt %.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: February 19, 2013
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Yuki Ikeda, Yasushi Ochiai
  • Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same
    Patent number: 8367835
    Abstract: Provided is a compound useful as a therapeutic drug for pain and inflammation caused by various pathological conditions such as neuropathic pain and rheumatoid arthritis. The compound of the formula (I) or a salt thereof [wherein R1 is a methyl group or a hydrogen atom, R2 represents a hydrogen atom, an alkyl group, an alkylcarbonyl group or an aryl carbonyl group, A represents a cycloalkyl group, a cycloalkenyl group, an aryl group or a heteroaryl group (each group may be substituted with a substituent selected from the group consisting of alkyl, alkenyl, cycloalkyl and halogen), n and m each represent an integer of 1, 2 or 3, and p represents an integer of 0, 1, 2 or 3].
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: February 5, 2013
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Yasunori Tsuzuki, Toshiya Morie, Takanori Nakamura, Isao Shimizu, Masanori Miyauchi
  • Tape preparation
    Patent number: 8354121
    Abstract: It is intended to provide a preparation for percutaneous administration of 2-(4-ethyl-1-piperazinyl)-4-(4-fluoro-phenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine (Compound A), which inhibits the generation of a metabolite and is capable of continuously maintaining a blood drug level. Specifically, a tape preparation comprising an adhesive layer formed on one surface of a support, characterized in that the adhesive layer contains (1) Compound A or a physiologically acceptable acid addition salt thereof, and (2) an acrylic adhesive, or (1) Compound A or a physiologically acceptable acid addition salt thereof, (2) an acrylic adhesive, and (3) a permeation enhancer is provided.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: January 15, 2013
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Hiroo Maeda, Naoki Ohara
  • DRUG FOR INFLAMMATORY BOWEL DISEASE
    Publication number: 20130004516
    Abstract: Anti-CD81 antibody displays not only a remission induction effect, but also a long-term remission maintenance effect on inflammatory bowel disease when administered in a single dose, and is therefore effective as a drug for maintaining remission from inflammatory bowel disease. Moreover, anti-CD81 antibody is effective as a drug for the prevention, amelioration and treatment of inflammatory bowel disease because it has preventive, therapeutic and ameliorating effects on refractory inflammatory bowel disease.
    Type: Application
    Filed: March 3, 2011
    Publication date: January 3, 2013
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventor: Takamasa Watanabe
  • Medicament for treating lung cancer
    Patent number: 8287918
    Abstract: Lung cancer can be treated effectively by combination of amrubicin or a pharmaceutically acceptable salt thereof with cisplatin.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: October 16, 2012
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Toshihiro Noguchi, Akemi Baba